We are live on
!
Find out more
PIM
Partner Investment Management Portfolio holdings
AUM
$13.9M
Turnover
66.25%
1-Year Est. Return
55.92%
This Fund
S&P 500
This Quarter
Est. Return
+12.7%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
-$179M
(-73%)
Cap. Flow
-$195M
Cap. Flow
% of AUM
-293.2%
Top 10 Holdings %
Top 10 Hldgs %
30.27%
Holding
112
New
25
Increased
15
Reduced
41
Closed
30
Avg Time Held Equity + Options
0.5
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$1.69M |
| 2 |
AerCap
AER
|
+$1.35M |
| 3 |
Pfizer
PFE
|
+$1.33M |
| 4 |
Illumina
ILMN
|
+$960K |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$934K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vulcan Materials
VMC
|
+$21.4M |
| 2 |
Microsoft
MSFT
|
+$18.6M |
| 3 |
Bausch Health
BHC
|
+$10.7M |
| 4 |
Macquarie Infrastructure Holdings, LLC
MIC
|
+$7.46M |
| 5 |
AGN
Allergan Inc
AGN
|
+$7.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.86% |
| 2 | Miscellaneous | 9.73% |
| 3 | Industrials | 8.93% |
| 4 | Materials | 5.71% |
| 5 | Technology | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CLVS
1
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.03M | 4.56% |
40,798
-23,454
| -37% | -$1.66M |
2013 Q2
7 quarters
|
|
|
2
Vulcan Materials
VMC
$33.4B
| $2.4M | 3.62% |
28,532
-277,494
| -91% | -$21.4M |
2014 Q1
4 quarters
|
|
|
3
Bausch Health
BHC
$2.36B
| $2.38M | 3.59% |
11,987
-60,519
| -83% | -$10.7M |
2013 Q2
7 quarters
|
|
4
DELISTED
Walgreens Boots Alliance
WBA
| $2.16M | 3.26% |
25,518
-77,984
| -75% | -$6.21M |
2014 Q4
1 quarter
|
|
5
DELISTED
Hologic
HOLX
| $1.81M | 2.73% |
54,971
-99,238
| -64% | -$3.05M |
2014 Q3
2 quarters
|
|
6
UnitedHealth
UNH
$360B
| $1.75M | 2.63% |
14,761
-25,196
| -63% | -$2.8M |
2014 Q4
1 quarter
|
|
|
7
Jazz Pharmaceuticals
JAZZ
$13.6B
| $1.7M | 2.56% |
+9,850
| New | +$1.69M |
2015 Q1
0 quarters
|
|
8
Edwards Lifesciences
EW
$49.9B
| $1.69M | 2.54% |
70,950
-145,086
| -67% | -$3.25M |
2014 Q4
1 quarter
|
|
|
9
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $1.64M | 2.47% |
19,898
-98,015
| -83% | -$7.46M |
2014 Q1
4 quarters
|
|
10
McKesson
MCK
$117B
| $1.54M | 2.31% |
6,792
-13,901
| -67% | -$3.08M |
2013 Q3
6 quarters
|
|
|
BRCM
11
DELISTED
BROADCOM CORP CL-A
BRCM
| $1.51M | 2.28% |
34,976
-132,592
| -79% | -$5.78M |
2014 Q4
1 quarter
|
|
12
Tenet Healthcare
THC
$21.5B
| $1.49M | 2.24% |
29,996
+18,739
| +166% | +$876K |
2013 Q3
6 quarters
|
|
|
KYTH
13
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
| $1.46M | 2.2% |
29,178
+4,722
| +19% | +$198K |
2013 Q2
7 quarters
|
|
|
14
AerCap
AER
$22.9B
| $1.4M | 2.11% |
+32,097
| New | +$1.35M |
2015 Q1
0 quarters
|
|
|
15
Pfizer
PFE
$169B
| $1.38M | 2.08% |
+41,874
| New | +$1.33M |
2015 Q1
0 quarters
|
|
16
HCA Healthcare
HCA
$99.3B
| $1.36M | 2.05% |
18,087
-90,367
| -83% | -$6.49M |
2013 Q2
7 quarters
|
|
17
Humana
HUM
$49.6B
| $1.33M | 2.01% |
7,483
-22,254
| -75% | -$3.52M |
2013 Q3
6 quarters
|
|
18
Stryker
SYK
$113B
| $1.3M | 1.97% |
14,142
-55,192
| -80% | -$5.14M |
2014 Q4
1 quarter
|
|
|
19
Illumina
ILMN
$39.6B
| $1.21M | 1.83% |
6,720
+5,099
| +315% | +$960K |
2014 Q4
1 quarter
|
|
20
Equifax
EFX
$18.9B
| $1.18M | 1.77% |
12,656
-2,075
| -14% | -$184K |
2014 Q4
1 quarter
|
|
21
Gilead Sciences
GILD
$194B
| $1.16M | 1.75% |
11,863
-49,468
| -81% | -$5.02M |
2013 Q2
7 quarters
|
|
22
Palo Alto Networks
PANW
$280B
| $1.14M | 1.71% |
46,662
-235,254
| -83% | -$5.27M |
2014 Q2
3 quarters
|
|
|
JUNO
23
DELISTED
Juno Therapeutics, Inc.
JUNO
| $1M | 1.51% |
18,032
-5,448
| -23% | -$264K |
2014 Q4
1 quarter
|
|
|
VAR
24
DELISTED
Varian Medical Systems, Inc.
VAR
| $960K | 1.45% |
+11,638
| New | +$934K |
2015 Q1
0 quarters
|
|
25
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
| $954K | 1.44% |
15,309
-102,322
| -87% | -$5.95M |
2014 Q1
4 quarters
|
|
Similar funds
SWM
ACM
ECAU
SL
DII
FIM
EM
BHC
Partner Investment Management's Q1 2015 Portfolio in Review
As of Q1 2015, Partner Investment Management held 112 positions worth $66.4M, down 73% from $245M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Partner Investment Management withdrew a net $195M in Q1 2015, closing 30 positions and reducing 41 holdings. Its most notable exit was Microsoft, an estimated $18.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 46% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Partner Investment Management opened a new position in Jazz Pharmaceuticals worth $1.7M.
- Partner Investment Management's largest Q1 2015 buy was Jazz Pharmaceuticals: 9,850 shares worth $1.7M.
- Partner Investment Management added most to Illumina in Q1 2015, an estimated $960K increase.
- Partner Investment Management's biggest Q1 2015 reduction was Vulcan Materials, cutting an estimated $21.4M.
- Partner Investment Management fully exited Microsoft in Q1 2015, selling an estimated $18.6M.
- Partner Investment Management's ten largest holdings make up 30% of its $66.4M portfolio in Q1 2015.
- Partner Investment Management opened 25 new positions and closed 30 in Q1 2015.
- Partner Investment Management's portfolio value fell 73% quarter-over-quarter to $66.4M.
Based on Partner Investment Management's 13F filing for Q1 2015, filed 15 May 2015.